Burgdorf – Ypsomed (SIX: YPSN) and Sidekick Health today announced a collaboration to extend Ypsomed’s device and SmartServices offering by implementing a self-injection module in Sidekick’s proven digital therapeutics solution. The combination of Ypsomed’s devices with Sidekick’s digital health behavioural economics and gamification expertise will form a unique solution delivering an engaging and personalized patient experience to people with chronic conditions, as well as a turn-key, best-in-class digital therapy management system to pharmaceutical customers.

Press Releases Ypsomed Group

Burgdorf – Ypsomed launches bolus delivery from the smartphone on the mylife YpsoPump via the mylife App. This new feature enables mylife YpsoPump users to deliver the bolus insulin conveniently and discreetly via their personal smartphone, without having to interact with the pump itself. Following the early summer launch of automated insulin delivery (AID) via the mylife CamAPS FX App, Ypsomed now offers an additional option for discreet remote bolus delivery to all users. People with diabetes now have the freedom to choose their preferred therapy solution.

Press Releases Ypsomed Group

Burgdorf – Ypsomed's Annual General Meeting on 29 June 2022 approved all the proposals of the Board of Directors. It elected Gilbert Achermann as the new Chairman of the Board of Directors and Simon Michel as a new member of the Board of Directors. The founder and long-standing Chairman Dr. h.c. Willy Michel was given a ceremonial farewell.

Burgdorf - Společnost Ypsomed spolupracuje se společností CamDiab Ltd., která je vývojářem aplikace CamAPS FX pro řízení hladiny glukózy prostřednictvím inzulínových pump s využitím adaptivního hybridního přístupu s uzavřenou smyčkou. V první polovině roku 2022 bude toto snadno použitelné řešení smyčky uvedeno na trh pro systém mylife YpsoPump, a to nejprve ve vybraných významných zemích Evropy a v průběhu roku budou následovat další teritoria. Pacienti pak mohou připojit systém mylife YpsoPump k mobilní aplikaci mylife CamAPS FX pro Android a je jim umožněna podpora podávání inzulínu na základě algoritmů včetně bolusu z osobního chytrého telefonu.

Ypsomed partners with CamDiab Ltd to drive on smartphone based adaptive automated insulin delivery (AID)

Burgdorf – Ypsomed partners with CamDiab Ltd, the developer of CamAPS FX, an app to manage glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach. During the first half of 2022, this easy-to-use loop solution will be launched for the mylife YpsoPump system, starting in selected major countries in Europe and followed by other territories in the course of the year. Patients can then connect the mylife YpsoPump system to the mylife CamAPS FX Android mobile application and are enabled to algorithm-based insulin delivery support including bolus from the personal smartphone.